Ying-Qin Li
Overview
Explore the profile of Ying-Qin Li including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
2167
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fang X, Zhong L, Jiang W, Huang C, Lei Y, Tang S, et al.
iScience
. 2024 Aug;
27(8):110431.
PMID: 39108708
Both concurrent chemoradiotherapy (CCRT) and induction chemotherapy (ICT) followed by CCRT are standard care of advanced nasopharyngeal carcinoma (NPC). However, tailoring personalized treatment is lacking. Herein, we established a radiogenomic...
2.
Li Q, Fang X, Li Y, Lin J, Huang C, He S, et al.
Adv Sci (Weinh)
. 2024 Jul;
11(36):e2403262.
PMID: 38973296
Despite docetaxel combined with cisplatin and 5-fluorouracil (TPF) being the established treatment for advanced nasopharyngeal carcinoma (NPC), there are patients who do not respond positively to this form of therapy....
3.
Chen K, Huang S, Yao J, He S, Gong S, Tan X, et al.
Drug Resist Updat
. 2024 Jun;
76:101111.
PMID: 38908233
Gemcitabine (GEM) based induction chemotherapy is a standard treatment for locoregionally advanced nasopharyngeal carcinoma (NPC). However, approximately 15 % of patients are still resistant to GEM-containing chemotherapy, which leads to...
4.
Huang S, Gong S, Zhao Y, Ye M, Li J, He Q, et al.
Nat Commun
. 2024 Jun;
15(1):5300.
PMID: 38906860
Chemoresistance is a main reason for treatment failure in patients with nasopharyngeal carcinoma, but the exact regulatory mechanism underlying chemoresistance in nasopharyngeal carcinoma remains to be elucidated. Here, we identify...
5.
Zhao Y, Lei Y, He S, Li Y, Wang Y, Hong X, et al.
Cells
. 2024 May;
13(10).
PMID: 38786107
In the original publication [...].
6.
Li Y, Song F, Zhong K, Yu G, Zilundu P, Zhou Y, et al.
J Mol Neurosci
. 2024 Feb;
74(1):27.
PMID: 38421552
No abstract available.
7.
Fang X, Li Q, Lin J, Huang C, Huang S, Tan X, et al.
Cell Death Dis
. 2024 Feb;
15(2):112.
PMID: 38321024
Despite that the docectaxel-cisplatin-5-fluorouracil (TPF) induction chemotherapy has greatly improved patients' survival and became the first-line treatment for advanced nasopharyngeal carcinoma (NPC), not all patients could benefit from this therapy....
8.
Liang Y, Zhao Y, Ding C, Huang S, Li Q, Zhu C, et al.
iScience
. 2023 Dec;
26(12):108467.
PMID: 38089590
Accurate risk stratification for patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC) is crucial for prognosis and treatment decisions. Here, we develop a tumor microenvironment-associated circular RNA (circRNA) signature that can...
9.
Huang C, Wang G, Lou J, Chen L, Li Q, Li K, et al.
Radiother Oncol
. 2023 Nov;
190:110032.
PMID: 38007040
Aim: Despite the high risk of tumor recurrence, patients with nasopharyngeal carcinoma (NPC) with persistently (at least twice) detected circulating cell-free Epstein-Barr virus (EBV) DNA levels during follow-up are routinely...
10.
Wen X, Liu X, Mao Y, Yang X, Wang Y, Zhang P, et al.
Theranostics
. 2023 Nov;
13(15):5545.
PMID: 37908717
[This corrects the article DOI: 10.7150/thno.28538.].